ArticleWorld journal of gastroenterology2003
Role of VEGF and CD44v6 in differentiating benign from malignant ascites.
Article in World journal of gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Diagnostic value of vascular endothelial growth factor (VEGF) levels in gastrointestinal cancers with ascites - A cross sectional study.Turkish journal of surgery · 2025Article
- Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.British journal of cancer · 2024Article
- A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.Journal of gastrointestinal cancer · 2017Article
- The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.Cancer cell international · 2017Article
- The clinical significance of vascular endothelial growth factor in malignant ascites.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Production and characterization of a peptide-based monoclonal antibody against CD44 variant 6.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2015Article
- Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.World journal of surgical oncology · 2014Article
- Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.Journal of clinical and translational hepatology · 2014Review
- Article
- Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression.Molecular cancer · 2012Article
- Vascular endothelial growth factor in malignant and benign pericardial effusion.Clinical cardiology · 2012Article
- Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cancer metastasis reviews · 2012Review
- Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma.Journal of cancer research and clinical oncology · 2010Article
- CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours.Journal of cellular and molecular medicine · 2010Article
- Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.Yonsei medical journal · 2008Article
- Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.World journal of gastroenterology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo detect the vascular endothelial growth factor (VEGF) and soluble splice variant 6 of CD44 (sCD44v6) levels in ascites and to explore their role in differentiating benign from malignant ascites.
methodsCirrhotic ascites (n=36), tuberculosis ascites (n=8) and malignant ascites (n=23) were collected and studied. Concentrations of soluble VEGF and sCD44v6 in various kinds of ascites (n=67) were measured using a sandwich enzyme-linked immunoadsorbent assay.
resultsVEGF and sCD44v6 levels in malignant ascites were 640.74+/-264.81 pg/ml and 89.22+/-38.20 ng/ml, respectively, both of which were significantly higher than those in cirrhotic ascites and tuberculous ascites (q=18.98, 11.89 and q=8.92, 5.09; P<0.01). However, the levels of VEGF and sCD44v6 in cirrhotic and tuberculous ascites had no significant difference (q=0.48, 0.75; P>0.05). Furthermore, VEGF levels in malignant ascites in patients with ovarian cancer were higher than those with gastric and colon cancer (q=5.03, 6.79; P<0.01, respectively). But differences of VEGF levels between gastric and colon cancer were not significant (q=1.90, P>0.05). Whereas, sCD44v6 levels in malignant ascites from patients with ovarian, gastric and colon cancer had no significant difference (q=0.06, 0.91, 0.35; P>0.05, respectively). In comparison with cirrhotic and tuberculous ascites, when the upper limit of its VEGF mean levels 119.44 pg/ml (70.90+/-48.54) and sCD44v6 mean levels 63.59 ng/ml (44.42+/-19.17) was taken as the minimum cutoff limit, the sensitivity and specificity of VEGF and sCD44v6 of this assay to the diagnosis of malignant ascites were 91.3%, 90.9% and 73.9%, 88.7% respectively.
conclusionElevated levels of VEGF and sCD44v6 may be useful in differential diagnosis of benign and malignant ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.